Search research articles
Contact Us
Filters
Showing results (221-230 of 264) with videos related to
Page
of 27
Sort By:
Cancer Cell
|
December 19, 2012
Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models
Ryan B Corcoran, Katherine A Cheng, Aaron N Hata, et al.
Cancer Discovery
|
October 29, 2013
mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1
Anthony C Faber, Erin M Coffee, Carlotta Costa, et al.
Nature
|
August 12, 2021
Cycling cancer persister cells arise from lineages with distinct programs
Yaara Oren, Michael Tsabar, Michael S Cuoco, et al.
Biorxiv : the Preprint Server for Biology
|
May 7, 2026
Dual inhibition of GTP-bound (ON) and GDP-bound (OFF) KRAS <sup>G12C</sup> suppresses PI3Kα and leads to potent tumor inhibition
Katherine Parker, Samar Ghorbanpoor, Wafa Malik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 23, 2020
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer
Ibiayi Dagogo-Jack, Satoshi Yoda, Jochen K Lennerz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2018
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer
Jessica J Lin, Viola W Zhu, Satoshi Yoda, et al.
Cancer Discovery
|
May 3, 2015
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor
Zofia Piotrowska, Matthew J Niederst, Chris A Karlovich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 4, 2025
STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20-Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer Models
Raymond A Pagliarini, Jack A Henderson, Benjamin C Milgram, et al.
Cell
|
February 7, 2025
GUK1 activation is a metabolic liability in lung cancer
Jaime L Schneider, Kiran Kurmi, Yutong Dai, et al.
Oncogene
|
July 21, 2019
Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer
Sana Raoof, Iain J Mulford, Heidie Frisco-Cabanos, et al.
Page
of 27
Search research articles
Search
Showing results (221-230 of 264) with videos related to
Sort By:
Page
of 27
Cancer Cell
|
December 19, 2012
Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models
Ryan B Corcoran, Katherine A Cheng, Aaron N Hata, et al.
Cancer Discovery
|
October 29, 2013
mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1
Anthony C Faber, Erin M Coffee, Carlotta Costa, et al.
Nature
|
August 12, 2021
Cycling cancer persister cells arise from lineages with distinct programs
Yaara Oren, Michael Tsabar, Michael S Cuoco, et al.
Biorxiv : the Preprint Server for Biology
|
May 7, 2026
Dual inhibition of GTP-bound (ON) and GDP-bound (OFF) KRAS <sup>G12C</sup> suppresses PI3Kα and leads to potent tumor inhibition
Katherine Parker, Samar Ghorbanpoor, Wafa Malik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 23, 2020
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer
Ibiayi Dagogo-Jack, Satoshi Yoda, Jochen K Lennerz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2018
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer
Jessica J Lin, Viola W Zhu, Satoshi Yoda, et al.
Cancer Discovery
|
May 3, 2015
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor
Zofia Piotrowska, Matthew J Niederst, Chris A Karlovich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 4, 2025
STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20-Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer Models
Raymond A Pagliarini, Jack A Henderson, Benjamin C Milgram, et al.
Cell
|
February 7, 2025
GUK1 activation is a metabolic liability in lung cancer
Jaime L Schneider, Kiran Kurmi, Yutong Dai, et al.
Oncogene
|
July 21, 2019
Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer
Sana Raoof, Iain J Mulford, Heidie Frisco-Cabanos, et al.
Page
of 27